Cardiol Therapeutics Inc.
TSX:CRDL.TODrug Manufacturers - Specialty & Generic
+$0.00 today
- Market cap
- $164.10M
- Beta
- 0.48
- P/E (TTM)
- -4.5
- EPS (TTM)
- -$0.33
Volume 0.08M
Average 0.12M
CRDL.TO Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Cardiol Therapeutics Inc.TSX: CRDL.TO
Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Free cash flow growth accelerates
Q1 FY2026 free cash flow of CA$7.57M (cash outflow) rose 5.6% year over year, ahead of the -4.1% change in trailing-twelve-month free cash flow. Sequentially, it rose 44.7% from the prior quarter. Over 3 fiscal years it compounded at -4.4% a year.
Context
- Free cash flow grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +5.6% holds above the trailing-twelve-month pace of -4.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
CAD · from the cash flow
- Latest · FY2025
- (23.88M) CAD
- Year-over-year change
- +4.8%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (23.88M) | +4.8% |
| FY2024 | 2024-12-31 | (25.08M) | -99255.9% |
| FY2023 | 2023-12-31 | (25.24K) | +99.9% |
| FY2022 | 2022-12-31 | (27.3M) | -15.8% |
| FY2021 | 2021-12-31 | (23.56M) | — |
Free Cash Flow vs competitors
How CRDL.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so free cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -4.1% is the lowest of 2, against a peer median of +68.7%.
- Over three fiscal years its annual growth of -4.4% compares with a peer median of +46.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
MSCL.TOSatellos Bioscience Inc. | LTM Mar 2026 | $25.78M USD | — | +60.7% | — |
| LTM Mar 2026 | CA$24.28M CAD | -4.1% | -4.4% | — | |
| LTM Mar 2026 | $18.11M USD | +68.7% | +32.5% | 32.5% | |
| Peer median (excluding CRDL.TO) | — | +68.7% | +46.6% | 32.5% | |
Competitors are the stored peer set for CRDL.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (31.64M) | (30.93M) | (28.13M) | (36.68M) | (33.82M) |
| Depreciation & Amortization | 220.42K | 219.91K | 248.36K | 373.11K | 101.98K |
| Deferred Income Tax | (4.92M) | 0 | (1.59M) | 0 | 0 |
| Stock-Based Compensation | 8.5M | 5.01M | 4.17M | 14.28M | 10.7M |
| Change in Working Capital | 76.52K | 5.75M | 746.8K | (931.57K) | (733.34K) |
| Accounts Receivables | (59.95K) | (144.18K) | 67.18K | (81.75K) | 135.43K |
| Inventory | 17.97K | (4.47M) | 0 | 0 | 0 |
| Accounts Payables | 2.39M | 4.47M | (1.29M) | (1.06M) | 263.69K |
| Other Working Capital | (2.27M) | 5.89M | 679.62K | 214.93K | (1.13M) |
| Other Non-Cash Items | 4.21M | (7.27M) | (627.28K) | (2.1M) | (105.34K) |
| Operating Cash Flow | (23.55M) | (27.22M) | (25.18K) | (25.06M) | (23.85M) |
| Capital Expenditures | (12.92K) | (74.71K) | (64) | (21.29K) | (24.48K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | (64.25K) | 0 | 0 |
| Investing Cash Flow | (12.92K) | (74.71K) | (64.31K) | (21.29K) | (24.48K) |
| Debt Repayment | (51.92K) | (53.93K) | (55.38K) | (41.53K) | (55.38K) |
| Common Stock Issued | 84.08M | 0 | 0 | 21.36M | 16.07M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 9.35M | 0 | (55.38K) | (2.47M) | (477.03K) |
| Financing Cash Flow | 93.44M | (53.93K) | (55.38K) | 18.84M | 15.54M |
| Effect of Forex Changes | (11.13K) | 2.92M | 762.04K | 1.89M | (824.04K) |
| Net Change in Cash | 69.87M | (24.43M) | (24.54M) | (4.35M) | (9.16M) |
| Free Cash Flow | (23.56M) | (27.3M) | (25.24K) | (25.08M) | (23.88M) |
Cardiol Therapeutics Inc.
TSX:CRDL.TO
Intrinsic Alpha fair value
Locked
Current Price
$1.36
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.